SiBone (NASDAQ:SIBN) Insider Anthony Recupero Sells 21,049 Shares

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 21,049 shares of SiBone stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $15.40, for a total value of $324,154.60. Following the transaction, the insider owned 243,418 shares in the company, valued at approximately $3,748,637.20. This represents a 7.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

SiBone Trading Up 3.2%

Shares of SIBN stock opened at $15.74 on Thursday. SiBone has a twelve month low of $12.49 and a twelve month high of $21.89. The stock has a market cap of $682.96 million, a price-to-earnings ratio of -30.86 and a beta of 0.69. The company’s 50-day moving average price is $17.97 and its 200-day moving average price is $16.86. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21.

Institutional Trading of SiBone

Several institutional investors have recently added to or reduced their stakes in SIBN. First Light Asset Management LLC raised its position in SiBone by 162.4% in the fourth quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock valued at $99,249,000 after purchasing an additional 3,115,001 shares during the period. American Century Companies Inc. grew its stake in shares of SiBone by 22.5% in the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock valued at $41,777,000 after buying an additional 521,683 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of SiBone by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock valued at $49,331,000 after buying an additional 11,566 shares during the period. Nuveen LLC raised its holdings in shares of SiBone by 5.1% in the 4th quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock valued at $28,041,000 after buying an additional 69,229 shares during the period. Finally, Impax Asset Management Group plc lifted its stake in SiBone by 17.1% during the 4th quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock worth $23,664,000 after acquiring an additional 175,000 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. TD Cowen upgraded shares of SiBone to a “strong-buy” rating in a report on Tuesday, January 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Truist Financial raised their target price on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Morgan Stanley upped their price target on SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Finally, Needham & Company LLC increased their price target on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.33.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.